anti-Myosin IIA (non-muscle) (heavy chain), mAb (recombinant antibody) (SF9)

Specifications / Handling

More Information
Product Details
Synonyms	Cellular Myosin Heavy Chain, Type A; Myosin Heavy Chain 9; Myosin Heavy Chain, Non-muscle IIa; Non-muscle Myosin Heavy Chain A
Product Type	Recombinant Antibody
Properties
Clone	SF9
Isotype	Human IgG2λ
Source/Host	Produced without the use of animals. Purified from HEK 293 cell culture supernatant.
Immunogen/Antigen	Full length myosin IIA from rat liver.
Application	Electron Microscopy ELISA Immunocytochemistry: (1:1000) Western blot: (1:1000)
Crossreactivity	Drosophila Human Mouse Rat
Specificity	Recognizes human, mouse, rat and drosophila myosin IIA (heavy chain).
Purity	≥95% (SDS-PAGE)
Purity Detail	Protein A-affinity purified.
Concentration	1mg/ml
Formulation	Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.
Isotype Negative Control	Fc (human) IgG2 Control (rec.)
Other Product Data	anti-Myosin IIA (non-muscle), monoclonal antibody (recombinant) (SF9) is composed of human variable regions (VH and VL) (λ-chain) of immunoglobulin fused to the human lgG2 Fc domain.
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Use/Stability	Stable for at least 1 month after receipt when stored at +4°C. Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

anti-Myosin IIA (non-muscle), monoclonal antibody (recombinant) (SF9) is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.

Product References

Recombinant antibodies selected against subcellular fractions to track endogenous protein dynamics in vivo: C. Nizak, et al.; Traffic 7, 739 (2003)
Delivery of antibodies to the cytosol: A.L.J. Marschall, et al.; mAbs 6, 943 (2014)

Call	+41 61 926 6040
Fax	+41 61 926 6049

anti-Myosin IIA (non-muscle) (heavy chain), mAb (rec.) (SF9)